Tumour-Infiltrating Lymphocytes in Colorectal Adenocarcinoma
AbstractSeveral studies have indicated that lymphocytes found in tumour area, known as TILs (tumour-infiltrating lymphocytes), can provide prognostic information in colorectal cancer (CRC). The purpose of this study was to evaluate degree of stromal TILs according to histological grading of CRC. This study used a cross sectional design method by taking random samples of data and formalin-fixed paraffin-embedded of colorectal adenocarcinoma patients treated in Dr. Wahidin Sudirohusodo Hospital and Hasanuddin University Hospital in Makassar during the period of 2014-2016. The histological grading of each sample was reviewed and TILs were assessed according to recommendation of the International TILs Working Group, 2014 on hematoxylin-eosin (H-E)-stained sections. Based on histological grading it was found that from 98 samples, 23 samples (23.5%) were well-differentiated, 66 samples (67.3%) were moderately differentiated, and 6 samples were (9.2%) poorly differentiated. While based on degree of TILs found that low- and moderate-score were 38 (38.8%) and 42 (42.9%) samples respectively, and high-score were 18 (18.4%) samples. Data were analysed using the Chi-square test and a p value of 0.865 (p > 0.05) was obtained and therefore it was concluded that there was no significant difference of degree of TILs according to histological grading of colorectal adenocarcinoma in this study.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., … Bray, F. (2015). Cancer incidence and mortality worldwide : Sources , methods and major patterns in GLOBOCAN 2012, 386. https://doi.org/10.1002/ijc.29210
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66(4), 683–691. https://doi.org/10.1136/gutjnl-2015-310912
WHO. (2014). Indonesia, cancer country profiles, 22–23.
Jakubowska, K., Kisielewski, W., & Koda, L. K. (2017). Stromal and intraepithelial tumor ‑ infiltrating lymphocytes in colorectal carcinoma, 6421–6432. https://doi.org/10.3892/ol.2017.7013
Yao, W., He, J., Yang, Y., Wang, J., Qian, Y., Yang, T., & Ji, L. (2017). The Prognostic Value of Tumor- infiltrating Lymphocytes in Hepatocellular Carcinoma : a Systematic Review and Meta- analysis. Scientific Reports, (July), 1–11. https://doi.org/10.1038/s41598-017-08128-1
Gooden, M. J. M., Bock, G. H. De, Leffers, N., Daemen, T., & Nijman, H. W. (2011). The prognostic influence of tumour-infiltrating lymphocytes in cancer : a systematic review with meta-analysis. British Journal of Cancer, 105(1), 93–103. https://doi.org/10.1038/bjc.2011.189
Mei, Z., Liu, Y., Liu, C., Cui, A., Liang, Z., Wang, G., … Li, C. (2014). Tumour-infiltrating inflammation and prognosis in colorectal cancer : systematic review and meta-analysis, (February), 1595–1605. https://doi.org/10.1038/bjc.2014.46
Bupathi, M., & Wu, C. (2016). Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. Journal of Gastrointestinal Oncology, 7(5), 713–720. https://doi.org/10.21037/jgo.2016.07.03
.Abbas, A. K., Lichtman, A., & Pillai, S. (2017). Cellular and Molecular Immunology (9th ed.). Philadelphia: Elsevier Inc.
Rozek, L. S., Schmit, S. L., Greenson, J. K., Tomsho, L. P., Rennert, H. S., Rennert, G., & Gruber, S. B. (2016). Tumor-Infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. Journal of the National Cancer Institute, 108(8), 1–8. https://doi.org/10.1093/jnci/djw027
Hyuk, L. J. (2012). Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer. Archives of Surgery, 147(4), 366. https://doi.org/10.1001/archsurg.2012.35
Deschoolmeester, V., Baay, M., Lardon, F., Pauwels, P., & Peeters, M. (2011). Immune Cells in Colorectal Cancer : Prognostic Relevance and Role of MSI, 377–392. https://doi.org/10.1007/s12307-011-0068-5
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., … Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014. Annals of Oncology, 26(2), 259–271. https://doi.org/10.1093/annonc/mdu450
Stanley R. Hamilton, M. D., & Lauri A. Aaltonen, M.D., P. D. (2000). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System (Vol. 18). https://doi.org/10.1183/09031936.01.00275301
.Marzouk, O., & Schofield, J. (2011). Review of histopathological and molecular prognostic features in colorectal cancer. Cancers, 3(2), 2767–2810. https://doi.org/10.3390/cancers3022767
Iseki, Y., Shibutani, M., Maeda, K., & Nagahara, H. (2018). A new method for evaluating tumor- infiltrating lymphocytes ( TILs ) in colorectal cancer using hematoxylin and eosin ( H-E ) - stained tumor sections, 1–12.
Shi, S., Wang, L., Wang, G., Guo, Z., Wei, M., & Meng, Y. (2013). B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells, 8(10), 1–11. https://doi.org/10.1371/journal.pone.0076012
Amersi, F., Agustin, M., & Ko, C. Y. (2005). Colorectal Cancer : Epidemiology , Risk Factors , and Health Services, 18(3), 133–140.
Dintinjana, R. D., Redzović, A., & Dintinjana, M. (2014). Molecular Pathways of Colorectal Carcinogenesis are Promising Mistery ?, 1–5. https://doi.org/10.4172/2157-2518.S10-003
Valentini, A. M., Pinto, F. Di, Cariola, F., Guerra, V., Caruso, M. L., & Pirrelli, M. (2018). PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments, 9(9), 8584–8596.
Rosenbaum, M. W., Bledsoe, J. R., Morales-Oyarvide, V., Huynh, T. G., & Mino-Kenudson, M. (2016). PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern Pathology, 29(9), 1104–1112. https://doi.org/10.1038/modpathol.2016.95
Huszno, J., N., E. Z., Lange, D., K., Z., & Nowara, E. (2017). The association of tumor lymphocyte infiltration with clinicopathological factors and survival in breast cancer, 68(1), 26–32.
Dong, Y., Sun, Q., & Zhang, X. (2017). PD-1 and its ligands are important immune checkpoints in cancer, 8(2), 2171–2186.
Passardi, A., Canale, M., Valgiusti, M., & Ulivi, P. (2017). Immune checkpoints as a target for colorectal cancer treatment. International Journal of Molecular Sciences, 18(6). https://doi.org/10.3390/ijms18061324
Guo, L., Lin, Y., & Kwok, H. F. (2017). The function and regulation of PD-L1 in immunotherapy. ADMET and DMPK, 5(3), 159. https://doi.org/10.5599/admet.5.3.442
Karwacz, K., Arce, F., Bricogne, C., Kochan, G., & Escors, D. (2012). PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy, 1(1), 86–88. https://doi.org/10.1002/emmm.201100165.www.landesbioscience.com
Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L., … You, Z. (2016). Expression of PD ‑ 1 , PD ‑ L1 and PD ‑ L2 is associated with differentiation status and histological type of endometrial cancer, 944–950. https://doi.org/10.3892/ol.2016.4744
Kawahara, T., Ishiguro, Y., Ohtake, S., Kato, I., Ito, Y., Ito, H., … Nakaigawa, N. (2018). PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low- grade cases : PD-L1 might function as a mediator of stage progression in bladder cancer, 1–6.
Masugi, Y., Nishihara, R., Yang, J., Mima, K., Da Silva, A., Shi, Y., … Ogino, S. (2017). Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut, 66(8), 1463–1473. https://doi.org/10.1136/gutjnl-2016-311421
Nishikawa, H., & Sakaguchi, S. (2010). Regulatory T cells in tumor immunity, 767, 759–767. https://doi.org/10.1002/ijc.2542
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.